Blog
RSS FeedPosted by Michael Wonder on 24 Jun 2021
PMPRB risks harming the health of Canadians by reducing access to new medicines
23 June 2021 - On June 21, Innovative Medicines Canada submitted six recommendations to the federal government as part of the ...
Posted by Michael Wonder on 05 Jun 2021
Put Canadians first by suspending the implementation of harmful drug pricing regulations
4 June 2021 - Innovative Medicines Canada calls on the federal government to suspend the implementation of the Patented Medicines ...
Posted by Michael Wonder on 24 Jan 2021
Canada’s drug makers rattle their sabers over a government plan to control medicine spending
21 January 2021 - A majority of pharmaceutical executives in Canada say new regulations designed to cut prescription drug spending ...
Posted by Michael Wonder on 21 Jan 2021
Industry pooling helps maintain affordability of high cost drugs despite significant inflationary pressures
21 January 2021 - In 2019, the Canadian Drug Insurance Pooling Corporation's (CDIPC) high-cost drug sharing framework provided coverage to ...
Posted by Michael Wonder on 09 Jan 2021
Health Canada postpones overhaul of drug pricing for 6 months
8 January 2021 - Changes meant to bring down price of prescription drugs pushed to 1 July 2021. ...
Posted by Michael Wonder on 15 Nov 2020
Drug makers offer Canada 1 billion dollars to scrap some pending pricing rules
16 November 2020 - The pharmaceutical industry has made a last-ditch C$1 billion ($761 million) proposal to the Canadian government ...
Posted by Michael Wonder on 24 Oct 2020
Health Canada releases final version of controversial regulations for controlling drug prices
23 October 2020 - After months of delay, Health Canada has released a final version of new regulations that are ...
Posted by Michael Wonder on 03 Sep 2020
Multiple factors will influence pricing for COVID-19 vaccine in Canada, says health economist
3 September 2020 - Conventional drug costing models are unlikely to apply when it comes to putting a price tag on ...
Posted by Michael Wonder on 10 Aug 2020
Return some excess drug revenues to employers, CLHIA says in submission to PMPRB
10 August 2020 - In its submission to the Patented Medicine Prices Review Board’s draft guidelines, the Canadian Life and ...
Posted by Michael Wonder on 04 Aug 2020
Innovative Medicines Canada responds to the revised draft PMPRB Guidelines consultation
4 August 2020 - The Patented Medicine Prices Review Board's revised Guidelines will result in patients losing access to innovative ...
Posted by Michael Wonder on 14 Jul 2020
PMPRB changes within scope of Patent Act, rules federal court in judicial review
13 July 2020 - The Federal Court has upheld reforms to the Patented Medicines Pricing Review Board that updated the ...
Posted by Michael Wonder on 30 Jun 2020
Canada federal court dismisses drug makers' plea challenging drug price rules
30 June 2020 - The federal court of Canada on Monday dismissed a plea by drug makers challenging the Canadian ...
Posted by Michael Wonder on 29 Jun 2020
IMC responds to Federal Court decision regarding PMPRB regulatory changes
29 June 2020 - Innovative Medicines Canada released the following statement today in response to the Federal Court of Canada’s ...
Posted by Michael Wonder on 22 Jun 2020
PMPRB publishes new draft guidelines, launches 30 day consultation
22 June 2020 - As reported earlier this month, the Patented Medicine Prices Review Board has published a new draft ...
Posted by Michael Wonder on 01 Jun 2020
Canada's new drug price rules pushed to next year
1 June 2020 - Canada's drug pricing agency said on Monday that new regulations aimed at lowering costs would come ...